期刊
PROGRESS IN RETINAL AND EYE RESEARCH
卷 80, 期 -, 页码 -出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.preteyeres.2020.100875
关键词
Glaucoma; Nerve fiber layer; Axonal degeneration; Retinal ganglion cell; Retinal imaging
资金
- National Institutes of Health [P30EY026877, R01EY028287, R01EY030361, R01EY025231, R01EY018875, U24EY029903, U01EY02726103, R01EY031469, R01EB029747, R01NS094681, R21NS105043]
- Medical Technology Enterprise Consortium [MT1800012]
- Glaucoma Research Foundation
- BrightFocus Foundation
- Gilbert Family Foundation
- Research to Prevent Blindness, Inc.
Glaucoma and other optic neuropathies involve progressive dysfunction and loss of retinal ganglion cells. Developing novel biomarkers for glaucoma is crucial for improving diagnosis and monitoring disease progression. Integrating exploratory biomarker outcomes into prospective therapeutic trials is a key step for the future.
Glaucoma and other optic neuropathies are characterized by progressive dysfunction and loss of retinal ganglion cells and their axons. Given the high prevalence of glaucoma-related blindness and the availability of treatment options, improving the diagnosis and precise monitoring of progression in these conditions is paramount. Here we review recent progress in the development of novel biomarkers for glaucoma in the context of disease pathophysiology and we propose future steps for the field, including integration of exploratory biomarker out-comes into prospective therapeutic trials. We anticipate that, when validated, some of the novel glaucoma biomarkers discussed here will prove useful for clinical diagnosis and prediction of progression, as well as monitoring of clinical responses to standard and investigational therapies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据